Condition
Ocular Hypertension (OHT)
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 13 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
13 shownREGN22530 for Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07675824 · 2026-09-08
RECRUITINGiDose TR Administration in an Office-Based Surgery SettingNCT07816692 · 2026-05-13
RECRUITINGDirect vs Standard SLT for Glaucoma: A Noninferiority TrialNCT07408154 · 2026-04-27
RECRUITINGSafety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery AloneNCT06848946 · 2025-01-13
RECRUITINGQlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT PatientsNCT06249152 · 2024-04-21
COMPLETEDQlaris Phase 2 Study of QLS-111 in POAG And/or OHT PatientsNCT06016972 · 2024-03-05
COMPLETEDStudy of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAGNCT02829996 · 2016-08-19
COMPLETEDStudy of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle GlaucomaNCT02565173 · 2015-09-01
COMPLETEDSafety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular HypertensionNCT02226094 · 2013-11-01
TERMINATEDA Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle GlaucomaNCT01917383 · 2013-08-01
COMPLETEDSingle and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle GlaucomaNCT01670266 · 2012-08-01
COMPLETEDAL-54478 Proof of Concept StudyNCT01318252 · 2011-06-01
COMPLETEDSafety Study of Latanoprost Slow Release InsertNCT01180062 · 2011-01-01
TERMINATEDCommon interventions
LatanoprostDRUG2AL-54478 0.005%DRUG1AL-54478 VehicleDRUG1Arm 2DRUG1Direct Selective laser TrabeculoplastyDEVICE1DWT device dose ADEVICE1DWT device dose BDEVICE1DWT shamDEVICE1Ellex Tango SLT machineDEVICE1Experimental: QLS-111 ophthalmic solution, (0.015%)DRUG1Experimental: QLS-111 ophthalmic solution, (0.03%)DRUG1Experimental: QLS-111 ophthalmic solution, (0.075%)DRUG1iDose TR (travoprost intracameral implant) 75 µgCOMBINATION_PRODUCT1iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgeryCOMBINATION_PRODUCT1latanoprost 0.0025% QDDRUG1Latanoprost 0.005%DRUG1latanoprost 0.005% QDDRUG1Latanoprost SR insertDRUG1ONO-9054DRUG1PlaceboDRUG1placebo BIDDRUG1QLS-111 ophthalmic vehicle solutionOTHER1QLS-111 vehicle ophthalmic solutionDRUG1QLS-111, 0.015%DRUG1QLS-111, 0.030%DRUG1
Leading sponsors
Trial status mix
COMPLETED7
RECRUITING4
TERMINATED2
Phase mix
PHASE27
PHASE14
NA1
PHASE31
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.